Approved comparison material connected to this topic.
6 total recordsSource comparisons are presented without a generated winner.
Hexarelin vs CJC-1295 for GH Research UK 2026 All peptide compounds referenced in this article are intended strictly for laboratory and academic research purposes. They are not approved for human use, All pept…
All peptide compounds referenced in this article are intended strictly for laboratory and academic research purposes. They are not approved for human use, therapeutic application, or clinical treatment. This c…
CJC-1295 is a synthetic GHRH analogue (29-amino acid peptide, MW ~3367 Da non-DAC, ~3647 Da DAC) that acts exclusively at the GHRH receptor (GHRHR). GHRHR is a class B GPCR coupled to Gαs-adenylyl cyclase-cAMP…
The desensitisation profiles of Hexarelin and CJC-1295 represent one of the most important distinctions for longitudinal research protocols. Hexarelin, due to its very high GHS-R1a affinity, drives rapid recep…
GHS-R1a is expressed not only in the pituitary but also in hypothalamic nuclei (arcuate, ventromedial, paraventricular), hippocampal CA1-CA3 and dentate gyrus, and cortical and subcortical regions. This periph…
The most dramatic mechanistic divergence between Hexarelin and CJC-1295 lies in cardiac biology. Hexarelin produces direct, GH-independent cardioprotection via CD36. In hypophysectomised (pituitary-ablated) ra…